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We used [“Cldihydrotetrabenazine, a new ligand for the type 2 vesicular monoamine transporter (vMAT2), with posi- 
tron emission tomography to study striatal monoaminergic presynaptic terminals in 4 patients with multiple system 
atrophy, 8 with sporadic olivopontocerebellar atrophy, and 9 normal control subjects. Specific binding in the striatum 
was significantly reduced in the multiple system atrophy patients as compared with the normal control group, with 
average reductions of 61% in the caudate nucleus (p = 0.002) and 58% in the putamen (p = 0.009). Smaller reductions 
were found in the sporadic olivopontocerebellar atrophy group, averaging 26% in the caudate nucleus (p = 0.05) and 
24% in the putamen (p = 0.1 1). Mean blood-to-brain [“Cldihydrotetrabenazine transport (K,) was significantly differ- 
ent between groups only in the cerebellum, with values for the sporadic olivopontocerebellar atrophy group diminished 
compared with the normal control group. Cerebellar K, was not significantly decreased in the multiple system atrophy 
group. The finding of reduced striatal W T 2  in sporadic olivopontocerebellar atrophy patients suggests nigrostriatal 
pathology, indicating that some may later develop symptomatic extrapyramidal disease. 
Cilman, S, Frey KA, Koeppe RA, Juiick L, Little R, Vander Borght TM, Lohnian M, 
Martorello S, Lee LC, Jewett DM, Kilbourn MR. Decreased striatal monoaminergic 
terminals in olivopontocerebellar atrophy and multiple system atiophy demonstrated 
with positron emission tomography. Ann Neurol 1996;40:885-892 
Multiple system atrophy (MSA) is a progressive neuro- 
logical disorder consisting of combinations of extra- 
pyramidal, pyramidal, cerebellar, and autonomic symp- 
toms and signs [l-71. The term “possible MSA” is 
used for patients with only extrapyramidal symptoms 
that are poorly responsive or unresponsive to levodopa 
(striatonigral degeneration [SND]) and patients with 
a combination of cerebellar ataxia and extrapyramidal 
symptoms [2].  The term “probable MSA’ pertains to 
patients with extrapyramidal symptoms poorly respon- 
sive or unresponsive to levodopa accompanied by auto- 
nomic symptoms with or without pyramidal and cere- 
bellar symptoms (Shy-Drager syndrome [SDS]) [2].  
Similarly, the term “probable MSA’ is applied to pa- 
tients with cerebellar and autonomic symptoms with 
or without extrapyramidal and pyramidal symptoms 
[2].  The diagnosis of “definite MSA’ requires a typical 
history and physical findings with subsequent postmor- 
tem verification [2].  In most patients with definite MSA, 
neuropathological examination demonstrates degenera- 
tivechanges in the cerebellum and brainstem as well as the 
basal ganglia and spinal cord [8]. The neuropathological 
changes in MSA include those seen with SND [9-121, 
SDS [3 ,  13-16], and olivopontocerebellar atrophy 
(OPCA) 13, 6-81. Neuronal loss and gliosis occur in the 
basal ganglia (putamen and globus pallidus), brainstem 
and cerebellum (substantial nigra, locus ceruleus, dorsal 
vagal nuclei, vestibular nuclei, inferior olives, pontine nu- 
clei, and cerebellar Purkinje cells), and spinal cord (py- 
ramidal tracts, intermediolateral columns, and Onuf‘s 
nuclei) [ 1,7, 8). Kecently, oligodendroglial [ 17-2 I ] and 
neuronal [22-241 intracytoplasmic and intranuclear in- 
clusions were observed with MSA. 
OPCA is a neurodegenerative disorder occurring 
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both sporadically (sOPCA) a n d  with dominant  
(dOPCA) and recessive (rOPCA) forms of hereditary 
transmission and  characterized by progressive ataxia of 
gait and  speech, disturbances of extraocular move- 
ments, and  difficulty with l imb coordination [25-291. 
T h e  neuropathological changes include loss of inferior 
olivary neurons and their climbing fiber projections t o  
the cerebellum, decreased numbers of pont ine neurons 
and their mossy fiber connections in  the cerebellum, 
and marked reduction o f  Purkinje cells a n d  granule 
cells [7, 30-321. Some patients initially diagnosed with 
sOPCA develop additional clinical signs characteristic 
of MSA, and  at  postmortem show degenerative changes 
not  only within the brainstem and cerebellum, but  also 
within the basal ganglia and  spinal cord [l-41. Most  
patients who present initially with OPCA a n d  later de- 
velop clinical manifestations of MSA have the sporadic 
and  not  the hereditary form of the disorder [2]. T h e  
percentage of  patients with sOPCA who later develop 
MSA is unknown, and  no method is currently available 
to  determine whether individual sOPCA patients will 
progress to develop MSA. Decreased striatal function 
that is not  accompanied by clinical evidence of extra- 
pyramidal disease might  be expected in sOPCA pa- 
tients who will develop MSA with time. A means of 
detecting striatal abnormalities i n  sOPCA patients 
would serve a useful function i n  permitting the distinc- 
tion of "pure" OPCA and MSA earlier in their courses 
and  thus in  assisting with the prognosis of the  disorder. 
The present investigation was designed to  determine 
whether positron emission tomography (PET) might 
be used t o  detect abnormalities in striatal monoaminer- 
gic presynaptic terminals i n  patients with sOPCA. 
Several radiopharmaceuticals have been utilized pre- 
viously with PET to examine monoaminergic presyn- 
aptic terminals, but medication use a n d  compensatory 
effects of disease processes affect the results. Re- 
cently our  center developed ["Cldihydrotetrabenazine 
(DTBZ) to examine the density of binding t o  the type 
2 vesicular monoamine transporter (VMAT2). Studies 
in animals suggested that this agent avoids the prob- 
lems from disease-related compensation or medications 
encountered with previously used agents [33-351. In  
the present study and  a companion investigation [35], 
this new ligand was utilized t o  determine whether the  
density of monoaminergic terminals in the striatum is 
decreased with normal aging and  in  Parkinson's dis- 
ease, in  MSA, and  i n  a t  least some patients with 
sOPCA. A preliminary version of the present study has 
been published 1361. 
Materials and Methods 
Putient Groups and Normal Subjects 
The Institutional Review Board approved the studies, and 
we obtained informed consent from each subject. Three 
groups were studied: 4 patients with probable MSA (age 71 
2 9 years, mean 2 standard deviation), 8 patients with 
sOPCA (age 55 2 9 years), and 9 normal control subjects 
(age 58 -t 10 years). The normal control subjects were se- 
lected on the basis of age from a larger group reported in 
the accompanying investigation, and included all subjects in 
the middle-age and elderly groups 1351. The control subjects 
had no history of neurological disorders and no abnormalities 
on general physical and neurological examinations. None of 
the patients or control subjects were receiving centrally active 
medications that influence studies of striatal VMAT2 bind- 
ing (Table 1). 
We studied 4 patients with probable MSA (see Table 1). 
The diagnosis of MSA was based on the demonstration of 
an extrapyramidal disorder with autonomic failure unrespon- 
sive or poorly responsive to levodopa (Patients 1 and 4,  see 
Table 1) or a levodopa-unresponsive extrapyramidal disorder 
with autonomic failure and cerebellar dysfunction (Patients 2 
and 3, see Table 1). The signs of disorders of extrapyramidal, 
cerebellar, and autonomic function were graded clinically as 
mild, moderate, or severe (see Table 1). We defined an extra- 
pyramidal movement disorder as the presence of at least two 
of the following: akinesia, rigidity, tremor, and hypokinetic 
speech. We defined cerebellar dysfunction as the presence of 
at least two signs, limb or gait ataxia along with ocular dys- 
metria and ataxic dysarthria. We defined autonomic failure 
by the presence of postural hypotension, sexual impotence 
(in males), or urinary incontinence without outflow obstruc- 
tion or disorders of bladder suspension. The criteria for pos- 
tural hypotension included an orthostatic drop of 30 mm 
Hg or more in systolic blood pressure and 20 mm Hg or 
more in diastolic blood pressure with an increase in heart 
rate of no more than I0 beatsimin [37]. Blood pressure and 
pulse were measured with the patient supine and again 2 
minutes after the patient assumed a standing position. None 
of the patients were taking medications that induce postural 
hypotension. 
Eight patients with sOPCA were studied. The diagnosis 
of sOPCA was based on a history of sporadically occurring 
progressive deterioration of cerebellar function manifested by 
at least two signs, limb or gait ataxia along with ocular dys- 
metria and ataxia dysarthria, in the absence of other disorders 
such as sensory loss adequate to cause ataxia, medications, 
toxins, evidence of a neoplasm in the cerebellum or else- 
where, or evidence of multiple sclerosis or other diseases that 
can cause progressive cerebellar ataxia. A careful family his- 
tory was taken to ensure that the disorder was sporadic. The 
diagnosis was assisted by finding cerebellar and brainstem 
atrophy in magnetic resonance images (MRIs) in all of the 
patients studied (see Table l),  but this was not essential be- 
cause OPCA can occur without demonstrable atrophy in an- 
atomical imaging studies [38]. Three women with sOPCA 
(Patients 9, 10, and 12) had mild degrees of urinary inconti- 
nence, but this was attributed to peripheral bladder mechan- 
ics and not to autonomic involvement. 
The patients were evaluated with a complete history, phys- 
ical examination, neurological examination, laboratory rests 
to exclude other diseases, and MRI to exclude demyelinative 
disease and structural abnormalities. Speech was evaluated as 
described previously [39]. Laboratory tests included a com- 
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Table 1. Clinical Features o f  the Patients with Multiple System Atrophy (MSA) and 
Sporadic Olivopontocerebelhr Atrophy (SOPCA)a 
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"Rating scale: - = normal; + = mild; + + = moderate; + + + = severe. Trace levels were rated as normal 
"Doscs are total received per day. 
plete blood cell count; serum profiles of hepatic and renal 
function; brainstem auditory, visual, and somatosensory 
evoked potentials; serum levels of vitamins E and B L 2  and 
folic acid, and studies of thyroid function. In patients with 
symptoms for less than 3 years, a search was made for an 
occult malignancy, including breast and pelvic examinations 
in women, prostate examination in men, acid phosphatase 
and prostate-specific antigen measurements, stool guaiac tests 
for occult blood, and chest x-ray studies. In addition, anti- 
Purkinje cell antibodies were sought in blood samples from 
patients with ataxia of less than 3 years' duration. All patients 
were evaluated with MRI to determine the extent of volume 
loss of the structures under study. The extent of volume loss 
was evaluated from the scans and is listed in Table 1. The 
neurological examinations were conducted by a neurologist 
(S.G.) blinded to the PET data. 
PET studies were conducted similarly for all subjects. A 
catheter was placed in a radial artery for blood sampling. 
Radioactive fiducial markers placed on the scalp were used 
to register the dynamic sequence of frames, correcting for 
any motion that occurred throughout the study. The subjects 
lay quietly on a table, with eyes open and ears unoccluded 
and alert but not speaking. The subjects were imaged with 
a Siemens ECAT EXACT-47 PET scanner, which has an 
intrinsic in-plane resolution of 6.0-mm full width at half 
maximum (FWHM) at the center of the field of view and 
an axial resolution of 5.0-mm FWHM. The reconstructed 
resolution is approximately 9.0-mm FWHM. Forty-seven 
planes with a 3.375-mm center-to-center separation were im- 
aged simultaneously. Attenuation correction was calculated 
by the standard ellipse method. 
Anatomically configured volumes of interest (VOIs) were 
identified in summed activity maps from 0 to 7.5 minutes 
after injection. VOIs were placed in identical areas on all 
frames of the realigned dynamic sequence of scans for the 
caudate nucleus, putamen, thalamus, cerebellar hemispheres, 
and frontal cortex. VOIs were acquired from three adjacent 
axial levels that best represented these structures. Data from 
the frontal cortex were used to normalize the data taken from 
Positron Emission Tomography Studies 
DTBZ in racemic form was synthesized by ["C]methylation 
of 9- Odesmethyldihydrotetrabenazine. We administered by 
intravenous bolus 18 2 1 mCi containing less than 50 pg 
of mass of DTBZ and collected arterial blood samples and 
a sequence of 15 scans over the following 60 minutes [35]. 
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other regions in order to reduce variability in the quantitative 
measures. 
Pharmacokinetic Analysis 
The VOI data were fitted to a three-compartment tracer ki- 
netic model using standard nonlinear least-squares parameter 
estimation. Kinetic rate constants K ,  to k,i and cerebral blood 
volume were fitted parameters. Analysis resulted in regionai 
estimates of ligand transport from plasma to brain (K,), 
which is highly correlated with Aow since the single-pass 
extraction fraction is approximately 50%0, and total tissue 
distribution volume (DV) of DTBZ relative to plasma (DV 
= (K,/k2’)(l + k;/kJ) [401. 
Data Analysis 
Determinations of DTAZ K, and DV in individual struc- 
cures were normalized to values from the frontal cortex, 
which contains very little VMAT2 and is relatively spared 
in the diseases under study. The regional total DV data were 
converted to spccific DV by computing the following: (Re- 
gional DV - Frontal DV)/Frontal DV. Differences in spe- 
cific binding between groups were tested with analysis of 
covariance (ANCOVA) adjusting for age, as explained below. 
A separate single-factor ANCOVA was tested for each of the 
four regions. For regions demonstrating a significant overall 
group difference, specific comparisons with two group t tests 
were performed between groups. Significance levels for indi- 
vidual comparisons were not corrected for multiple compari- 
sons, and no corrections were made for the effects of tissue 
atrophy. 
Age Effects 
In a concurrent investigation utilizing racemic DTBZ, we 
found a significant decline of striatal DV values with increas- 
ing age in a sampling of normal control subjects with a 
broader age range [35]. Accordingly, we utilized ANCOVA 
to adjust for age in our analysis, even though, in the subset 
studied, more limited ranges in age were included, and age 
was not significantly associated with the values of K, or spe- 
cific binding in regions in which they distinguished the 
groups ( p  > 0.05 in all cases). The adjustment for age had 
only minor effects on the results. 
Results 
[I’ CIDihydrotetra benazine Speczj5c Binding 
ANCOVA revealed significant differences between 
groups in the caudate nucleus (F2,,; = 7.2, p = 0.005) 
and putamen (F2,,, = 4.9, p = 0.02) but not in the 
thalamus or cerebellum ( p  > 0.20). Adjusted means 
in the caudate nucleus and putamen were ordered as 
follows: MSA < sOPCA < control (Table 2, Figs 1, 
2). Specifically, in the MSA group, the adjusted mean 
values for the caudate nucleus and putamen were sig- 
nificantly decreased in comparison to those for both 
normal control subjects and sOPCA patients. The 
magnitude of the decreases in specific binding below 
normal values in the MSA subjects averaged 61% in 
the caudate nucleus ( p  = 0.002) and 58% in the puta- 
men ( p  = 0.009). Individual specific binding values 
Tab1e 2. [‘I C’Dihydvotetrdbenazine Specific Binding‘ 
~ ~~ 
Caudarc 
Group Nucleus l’uramen Thalamus Cerebellum 
Control 0.79 t 0.16 0.78 t 0.22 0.06 t 0.05 -0.04 i 0.12 
sOPCA 0.5H t 0.23h 0.60 t 0.23 0.03 t 0.06 -0.09 i 0.09 
(I1 = 9) 
(I1 = 8) 
(n = 4) 
MSA 0.30 t 0.16‘ 0.33 t 0.21’’ 0.05 2 0.16 -0.17 Z 0.17 
.‘Values represent the mean i srandard drviatlon. Means are age adjused by analy- 
sis of Cnvariance. 
ignificaiitly differeor froni normal control value, p = 0.05. 
‘Significanrly different from normal conri-oI value, p = 0.002. 
“Significantly different from nornial control value, p = 0.00‘). 
sOl’CA = sporadic (,livopontocerehellar atrophy; MSA = mulriple sysrem :atrophy. 
hS’ 
in the caudate nucleus were reduced by more than 3 
standard deviations below the normal control mean in 
3 of the 4 MSA subjects. Specific binding in the puta- 
men was reduced by more than 2.5 standard deviations 
in each of the same 3 patients. The fourth MSA pa- 
tient, corresponding to the uppermost point in each of 
the four regions plotted in Figure 2, had relatively low 
specific binding values in the frontal cortex, and thus 
the data for this patient appear less decreased after nor- 
malization than before. For this patient, normalization 
of the values in the caudate nucleus and putamen to 
a different brain region such as the thalamus resulted 
in striatal decreases that were nearly equivalent to 
those of the other 3 MSA patients. Independent evalu- 
ation of the MRIs of all 4 MSA patients by two of us 
(S. G., K. A. F.) blinded to the PET data revealed no 
greater evidence of frontai cortical atrophy in this pa- 
tient than the other 3. Thus, the findings in this pa- 
tient do not appear to result from the effects of partial 
volume averaging owing to tissue atrophy. 
In the sOPCA group the mean decrease of specific 
binding in comparison to the normal control values 
was not as great as in MSA, averaging 26% for the 
caudate nucleus ( p  = 0.05) and 24% for the putamen 
( p  = 0.11) (see Table 2).  Individual striatal specific 
binding values in sOPCA patients were more variable 
than those in MSA, with values for only 2 of 8 patients 
falling lower than 2 standard deviations below the con- 
trol group mean for the caudate nucleus, and values 
for only 1 of 8 for the putamen. 
f” CIDihydrotetrubenuzine Trdnsport (KJ 
Analysis of variance revealed significant differences be- 
tween groups only in the cerebellum (F2,,, = 6.4, p = 
0.008), where the means were in the following order: 
sOPCA < MSA < control. Subsequent pair-wise test- 
ing revealed that the only significant difference in cere- 
bellar K1 between groups was a decrease in the sOPCA 
group as compared with the normal control group (Ta- 
ble 3 ) .  Although the MSA group showed no significant 
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Fig I .  Distribution volume of ["C]dihydrotetrabenazine ([C-1 11DTBZ DV) in the basal ganglia (upper row) and cerebellum 
(lower row) of a 69-year-old male normal control subject, compared to a GO-year-old woman with sporadic olivopontocerebellar 





.- N - 
m 
differences from control values, cerebellar K1 values for 
2 of the 4 MSA patients were decreased to levels as 
low as the sOPCA values, but values for the other 2 
were within the range of the normal control values. 
The 2 MSA patients with low cerebellar K, values had 
clinical signs of cerebellar dysfunction in addition to 
extrapyramidal and autonomic disturbances, whereas 
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Discussion 
Many previous studies showed evidence of both striatal 
degeneration and decreased density of striatal mono- 
aminergic presynaptic terminals in MSA. Investigations 
utilizing [ '8F]fluorodeoxyglucose (FDG) to examine lo- 
cal cerebral metabolic rates for glucose revealed hypo- 
metabolism in the striatum 141-441 and also in the 
cerebral cortex [42, 44, 451, cerebellum [44-461, thala- 
mus [44], and brainstem [44]. PET studies with 
[18F]fluorodopa in MSA patients revealed diminished 
striatal uptake, suggesting that nigrostriatal dopaminer- 
gic terminals are damaged [47-491. 
E 













Caudate Putamen Thalamus Cerebellum 
Fig 2. Specijic binding of ["C]dihydrotetrabenazine normal- 
ized to the fiontal cortex (FCtx) in the caudate nucleus, puta- 
men, thalamus, and cerebellum of individual normal control 
subjects (filled triangles) compared to patients with sporadic 
olivopontocerebellar atrophy (sOPCA, open circles) and 
patients with multiple system atrophy (MSA, filled circles). 
The horizontal bars indicate -+ 2 standard deviations about 
the normal control group mean. 
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Table 3. [I’ CjDibydrotetrabenazine Plasma-to-Brain 
Transport (KJ Normalized to Frontal Cortexa 
~~~ 
Caudate 
Group Nucleus Putamen Thalamus Cerebellum 
Control 1.00 i 0.12 1.08 + 0.13 1.25 i 0.07 1.00 2 0.13 
sOPCA 1.02 +- 0.09 1.11 2 0.05 1.25 .t 0.13 0.73 2 0.15” 
MSA 1.02 +- 0.14 1.09 2 0.15 1.22 t 0.09 0.91 i 0.20 
“Values represent the mean 2 standard deviation in the patients identi- 
fied in Table 1. Means are age adjusted by analysis of covariance. 
bSignificantly different from normal control value, p = 0.002. 
sOPCA = sporadic olivopontocerebellar atrophy; MSA = multiple sys- 
tem atrophy. 
Some evidence suggests that, similar to MSA pa- 
tients, certain sOPCA patients have striatal degenera- 
tion, even though clinical signs of striatal injury are 
not evident in sOPCA. In a study with FDG and PET, 
MSA and sOPCA patients showed similar levels of hy- 
pometabolism in the striatum as well as the cerebral 
cortex, thalamus, brainstem, and cerebellum [44]. A 
PET study with [‘*F]fluorodopa of patients with the 
predominantly cerebellar form of probable MSA re- 
vealed decreased striatal uptake of [ ’8F]fluorodopa even 
though striatal dysfunction was not the principal clini- 
cal manifestation [49]. The patients described in that 
report most likely had a disorder similar to the sOPCA 
patients in the present study. Our investigation was 
undertaken to utilize PET with a newly developed li- 
gand, DTBZ, to determine whether the density of do- 
paminergic presynaptic terminals in the striatum is de- 
creased in MSA and sOPCA. The form of DTBZ used 
in the present study is a racemic mixture, which has 
the disadvantage of a relatively high level of nonspecific 
binding. Our center has been successful in separating 
the enantiomers of DTBZ and has verified that the 
(+) form is responsible for the specific activity. Cur- 
rently this form is in use, and the ratio of specific to 
nonspecific activity is approximately twice the level of 
the racemic mixture of DTBZ. Although DTBZ does 
not differentiate between dopaminergic, noradrenergic, 
or serotonergic terminals, the concentration of dopa- 
minergic terminals in the striatum is very much higher 
than that of noradrenergic or serotonergic terminals; 
thus, the ligand serves as an excellent marker of the 
density of striatal dopaminergic endings [50]. 
Studies in animals suggested that DTBZ permits ex- 
amination of the density of the VMAT2 binding site 
without effects from medication and the compensatory 
effects of disease processes, which can influence the re- 
sults of studies with [‘*F]fluorodopa, WIN, and carbo- 
methoxy-3-P-(4-lodophenyl)tropane (PCIT) [33-351. 
Although the findings in animals have not been con- 
firmed in human studies as yet, there is no reason to 
anticipate different results because the mechanisms of 
binding site regulation in the setting of disease or med- 
ications are generally not species specific. 
The results of the present study, which should be 
treated as suggestive rather than definitive given the 
small sample sizes, provide evidence of reduced density 
of monoaminergic terminals in some sOPCA patients, 
and give encouraging information concerning the util- 
ity of DTBZ in detecting striatal disease by measuring 
the density of monoaminergic presynaptic terminals. 
Utilizing only 4 patients with MSA and 8 with sOPCA 
compared with 9 normal control subjects, the study 
demonstrated significantly reduced DV in the caudate 
nucleus of both groups and in the putamen of the 
MSA group. Ligand K, did not differ between groups, 
suggesting that the differences in specific binding in 
the striatum likely do not result from the effects of 
tissue atrophy. The reductions of DTBZ DV in the 
striatum were greater in the MSA than the sOPCA 
group. The sOPCA group had a wide range of specific 
binding in the striatum, suggesting varying degrees of 
striatal dysfunction within this group. In contrast, all 
4 MSA patients had deficits of striatal DTBZ specific 
binding, and all had correspondingly severe distur- 
bances of extrapyramidal function associated with au- 
tonomic failure. The weaker evidence of decreased 
DTBZ specific binding in the sOPCA group suggests 
that at least some of the sOPCA patients had de- 
creased nigrostriatal dopaminergic presynaptic termi- 
nals, which is in keeping with the clinical findings of 
trace levels of rigidity in Patients 7, 9, 1 I ,  and 12 and 
minimally detectable evidence of hypokinetic speech in 
Patients 5 ,  6, 7, 9, 10, and 12. Perhaps the sOPCA 
patients with reduced DTBZ specific binding will pro- 
ceed over time to develop extrapyramidal symptoms as 
well as the autonomic symptoms and signs characteris- 
tic of MSA. 
Even though the MSA patients on average had 
greater reductions of striatal DTBZ specific binding 
than did the sOPCA patients, several of the latter had 
decreased levels, some of which were reduced to the 
range observed in the MSA patients. As mentioned ear- 
lier, in a previous study [49],  [‘8F]fluorodopa was used 
to investigate dopaminergic presynaptic terminals in 
patients with the “olivopontocerebellar atrophy form 
of multiple system atrophy” who probably are similar 
to the patients with sOPCA in the present study. Re- 
view of the data in that study reveals that most of the 
patients who had decreased [‘8F]fluorodopa binding 
showed no signs of extrapyramidal disorder on clinical 
examination. The results in that study may have been 
affected by compensatory upregulation of dopa decar- 
boxylase activity and thus may have underestimated the 
decrease of nigrostriatal terminals in sOPCA. For a li- 
gand to be helpful, it should be sensitive to differentiat- 
ing disease from normal, which requires a favorable 
signal-to-noise ratio, and it should be accurate in esti- 
mating the severity of disease, which requires absence 
of bias. Upregulation decreases the “signal” (ix., the 
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difference between the disease state and normal) and 
probably decreases the sensitivity of the fluorodopa 
method for detecting loss of nigrostriatal terminals. 
Moreover, upregulation introduces bias, leading to in- 
accurate results. 
In the present study, the finding of similar levels of 
decline of DTBZ DV in some of the patients with 
sOPCA as compared with the MSA group raises the 
issue of why at least a few of these sOPCA patients 
did not show clinical signs of extrapyramidal dysfunc- 
tion. One possible explanation is that the changes in 
sOPCA were greater in the caudate nucleus than the 
putamen, whereas it seems likely that abnormal func- 
tion of the putamen is more strongly related to clinical 
signs of extrapyramidal dysfunction. Another possibil- 
ity is that other sites of neural degeneration in the ex- 
trapyramidal motor system could mask the clinical ex- 
pression of extrapyramidal disorder. These may include 
striatal neurons, but could also involve neurons in the 
subthalamus and globus pallidus. 
All sOPCA patients in this study had clinical evi- 
dence of cerebellar dysfunction without symptoms or 
signs of extrapyramidal disease and without autonomic 
disorders. The consistent involvement of the cerebel- 
lum in these patients accounts for the significant de- 
crease of K, in the sOPCA group as compared with 
both the MSA and normal control groups. Only 2 of 
the 4 MSA patients showed clinical signs of cerebellar 
dysfunction, indicating that these patients probably 
had degenerative changes in the cerebellum. The other 
2 MSA patients probably had mild or no degenerative 
changes in the cerebellum, and this may explain the 
lack of significant K, effects observed in the cerebellum 
of the MSA patients as a group. 
These investigations were suppported by grant DE-FG02- 
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